Reply to 'The case for evidence-based medicine for the association between hyperuricaemia and CKD'

Affiliations

¹ Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
² Division of Pediatric Nephrology, University of Alabama, Birmingham, AL, USA.
³ Division of Nephrology, Department of Medicine, University Hospital Limerick, Limerick, Ireland.
⁴ Graduate Entry Medical School, University of Limerick, Limerick, Ireland.
⁵ Division of Nephrology Department of Internal Medicine, Ewha Womans University College of Medicine Ewha Medical Research Center, Seoul, Korea.
⁶ Division of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL, USA.
⁷ Dept. Cardio-Renal Physiopathology, INC Ignacio Chavez, Mexico City, Mexico.
⁸ Department of Cardiology and Intensive Care Unit, Toranomon Hospital, Tokyo, Japan.
⁹ Department of Medicine, University of Bologna, Bologna, Italy.
¹⁰ Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. richard.johnson@cuanschutz.edu.
¹¹ Rocky Mountain Regional VA Medical Center, Aurora, CO, USA. richard.johnson@cuanschutz.edu.

Comment

Yuka Sato et al. Nat Rev Nephrol. 2020 Jul.

. 2020 Jul;16(7):422-423.

doi: 10.1038/s41581-020-0289-2.

¹ Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
² Division of Pediatric Nephrology, University of Alabama, Birmingham, AL, USA.
³ Division of Nephrology, Department of Medicine, University Hospital Limerick, Limerick, Ireland.
⁴ Graduate Entry Medical School, University of Limerick, Limerick, Ireland.
⁵ Division of Nephrology Department of Internal Medicine, Ewha Womans University College of Medicine Ewha Medical Research Center, Seoul, Korea.
⁶ Division of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL, USA.
⁷ Dept. Cardio-Renal Physiopathology, INC Ignacio Chavez, Mexico City, Mexico.
⁸ Department of Cardiology and Intensive Care Unit, Toranomon Hospital, Tokyo, Japan.
⁹ Department of Medicine, University of Bologna, Bologna, Italy.
¹⁰ Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. richard.johnson@cuanschutz.edu.
¹¹ Rocky Mountain Regional VA Medical Center, Aurora, CO, USA. richard.johnson@cuanschutz.edu.

No abstract available

Comment on

The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.
Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Ejaz AA, Sánchez-Lozada LG, Kuwabara M, Borghi C, Johnson RJ. Sato Y, et al. Nat Rev Nephrol. 2019 Dec;15(12):767-775. doi: 10.1038/s41581-019-0174-z. Epub 2019 Jul 11. Nat Rev Nephrol. 2019. PMID: 31296965 Review.
The case for evidence-based medicine for the association between hyperuricaemia and CKD.
Steiger S, Ma Q, Anders HJ. Steiger S, et al. Nat Rev Nephrol. 2020 Jul;16(7):422. doi: 10.1038/s41581-020-0288-3. Nat Rev Nephrol. 2020. PMID: 32313212 No abstract available.

1. Sato, Y. et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat. Rev. Nephrol. 15, 767–775 (2019). - DOI
1. Steiger, S., Ma, Q. & Anders, H.-J. The case for evidence-based medicine for the association between hyperuricaemia and CKD. Nat Rev. Nephrol. https://doi.org/10.1038/s41581-020-0288-3 (2020). - DOI - PubMed
1. Yood, R. A., Ottery, F. D., Irish, W. & Wolfson, M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res. Notes 7, 54 (2014). - DOI
1. Liu, X. et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren. Fail. 40, 289–297 (2018). - DOI
1. Tan, Y., Fu, J., Liang, M., Lin, Z. & Huang, J. Clinical observation of the effect of allopurinol to protect renal function in patients with diabetic nephropathy. Mod. Hosp. 11, 36–38 (2011).